Sign in
CompletedPhase 3

Efficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic Dermatitis

Key facts

Who runs it
Polisorb Joint Stock Company
Where
Russia7 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
161 people enrolled
Started
10 Apr 2024
Ended
28 Nov 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Colloidal Silicon Dioxide
  • Basic Therapy for Atopic Dermatitis
Record updated
10 November 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Adults aged 18 to 65 years
  • Diagnosis of mild to moderate atopic dermatitis
  • Compliance with the study protocol requirements
  • Provision of written informed consent

Who cannot take part

  • Contraindications to the study treatment or concomitant therapy, as specified in the study protocol
  • Failure to meet the inclusion criteria
  • Other conditions or circumstances that, according to the study protocol, could interfere with participation or the assessment of treatment efficacy and safety

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This multicenter, open-label, randomized Phase III clinical trial evaluated the efficacy and safety of adding Polisorb® MP, an oral colloidal silicon dioxide adsorbent, to basic therapy in adults with mild to moderate atopic dermatitis.

Read full original descriptionShow less

The study included 161 patients in the efficacy analysis. Participants were randomly assigned to receive either basic therapy alone (81 patients) or basic therapy in combination with Polisorb® MP (80 patients). Basic therapy included skin care with emollients and pharmacological treatment, including cetirizine and topical pimecrolimus. The treatment period lasted 14 days, followed by an observation period. The primary endpoint was the change in the SCORAD index from baseline to Day 14. Itch intensity, dermatology-related quality of life, EASI and IGA scores were also assessed.

Both groups showed improvement in disease severity during treatment. The mean SCORAD score decreased by 21.5 points in patients receiving Polisorb® MP in addition to basic therapy, compared with 17.7 points in patients receiving basic therapy alone. The difference between the groups was statistically significant (p = 0.0028), favoring the addition of Polisorb® MP. Improvements in itch intensity and IGA scores also favored combination therapy, while differences between groups in EASI changes and changes in dermatology-related quality of life were not statistically significant.

A total of 34 adverse events were reported in 26 patients. No serious adverse events or deaths were reported. Gastrointestinal events, particularly constipation, were more frequent in the Polisorb® MP group. Other reported events included difficulty with defecation, abdominal discomfort, bloating, dry mouth and nausea. No new or unexpected safety concerns specific to Polisorb® MP were identified during the study.

The findings indicate that adding Polisorb® MP to basic therapy was associated with a greater reduction in SCORAD scores over 14 days than basic therapy alone. The results should be interpreted in the context of the open-label design and the short treatment period.

The 2 groups in the trial

  • Basic Therapy AloneExisting treatment, for comparison

    Participants received basic therapy for atopic dermatitis, including emollient skin care and pharmacological treatment with cetirizine and topical pimecrolimus. The treatment period lasted 14 days, followed by an observation period.

    Treatment: Basic Therapy for Atopic Dermatitis

  • Basic Therapy in Combination with Polisorb® MPTreatment being tested

    Participants received Polisorb® MP in combination with basic therapy for atopic dermatitis, including emollient skin care and pharmacological treatment with cetirizine and topical pimecrolimus. The treatment period lasted 14 days, followed by an observation period.

    Treatment: Colloidal Silicon Dioxide and Basic Therapy for Atopic Dermatitis

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Multicenter Open-label Randomized Trial With an Active Control Group to Evaluate the Efficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic Dermatitis
Record updated
10 November 2026